儿童心脏移植后严重血流动力学障碍排斥与移植物衰竭
基于儿童心脏移植研究(PHTS)2005至2015年3259例受者数据,309例(9.5%)发生至少一次严重血流动力学障碍排斥(RSHC)。RSHC后5年移植物存活率45.7%,RSHC后心脏移植物血管病(CAV)是移植物衰竭的唯一预测因素,晚期RSHC预后更差。
要点
- RSHC后5年移植物存活率仅45.7%,当前治疗时代死亡率仍高。
- RSHC后CAV是移植物衰竭的唯一预测因素(HR 7.78)。
- 晚期RSHC(移植1年后)比早期RSHC预后更差,5年存活率39.0% vs 50.5%。
核心结论
- 当前治疗时代RSHC后死亡率仍高,5年移植物存活率45.7%。
- RSHC后CAV是移植物衰竭的唯一预测因素。
- 晚期RSHC患者预后差于移植后1年内发生RSHC者。
研究设计与样本
- 回顾性分析儿童心脏移植研究(PHTS)2005年1月至2015年12月3259例心脏移植受者数据。
- 采用Cox比例风险回归模型分析RSHC发生时间,CAV作为时间依赖协变量分析。
主要发现
- 309例(9.5%)发生至少一次RSHC,其中143例首次RSHC在移植后1年内。
- RSHC后5年移植物存活率45.7%;早期RSHC为50.5%,晚期RSHC为39.0%。
- RSHC对早期CAV的风险比(HR)为7.78(95%CI 5.82-10.40),其他类型排斥为2.31(95%CI 1.79-3.00)。
- 晚期RSHC患者RSHC后4年移植物丢失风险增加(HR 7.12;95%CI 2.18-23.22)。
关键数值与推荐
- RSHC独立危险因素:移植时年龄1-5岁(HR 1.51;95%CI 1.04-2.18)、年龄>10岁(HR 1.83;95%CI 1.29-2.60)、黑种人(HR 1.64;95%CI 1.25-2.15)、既往心脏手术(HR 1.55;95%CI 1.03-2.31)、移植时心室辅助装置支持(HR 1.65;95%CI 1.18-2.29)、维持激素治疗(HR 1.39;95%CI 1.06-1.82)、受者使用正性肌力药/血管加压药/甲状腺激素(HR 1.45;95%CI 1.09-1.94)。
临床怎么用
- 对具有RSHC危险因素(如移植时年龄1-5岁或>10岁、黑种人、既往心脏手术、VAD支持、维持激素、正性肌力药/血管加压药/甲状腺激素使用)的儿童心脏移植受者应加强监测。
- RSHC后应重点监测和防治CAV,因其是移植物衰竭的唯一预测因素。
- 晚期RSHC患者需更密切随访,警惕移植物丢失风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rejection with severe hemodynamic compromise (RSHC) carries a mortality risk approaching 50%. We aimed to identify current risk factors for RSHC and predictors of graft failure after RSHC. METHODS: Data from 3,259 heart transplant (HT) recipients between January 2005 and December 2015 in the Pediatric Heart Transplant Study (PHTS) were analyzed. Predictors for RSHC and outcome after RSHC were sought. Time to RSHC was analyzed using the Cox proportional hazards regression model. Cardiac allograft vasculopathy (CAV) after HT and CAV after RSHC were analyzed as time-dependent covariates. Timing of RSHC was analyzed as occurring before and after 4 years after RSHC. RESULTS: There were 309 patients (9.5%) with ≥ 1 RSHC episodes. In 143 patients with RSHC, the first episode was within 1 year after HT. Independent risk factors for RSHC were age 1 to 5 years at HT (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.04-2.18), age > 10 years at HT (HR, 1.83; 95% CI, 1.29-2.60), black race (HR, 1.64; 95% CI, 1.25-2.15), prior cardiac surgery (HR, 1.55; 95% CI, 1.03-2.31), ventricular assist device support at HT (HR, 1.65; 95% CI, 1.18-2.29), maintenance steroids (HR, 1.39; 95% CI, 1.06-1.82), and recipient on inotropes, pressors, or thyroid hormones (HR, 1.45; 95% CI, 1.09-1.94). Graft survival at 5 years after RSHC was 45.7%. RSHC was a greater risk factor for earlier CAV (HR, 7.78; 95% CI, 5.82-10.40) than other rejection types (HR, 2.31; 95% CI, 1.79-3.00). Patients with late RSHC, after 1 year after RSHC had increased risk of graft loss 4 years after RSHC (HR, 7.12; 95% CI, 2.18-23.22). The 5-year graft survival after RSHC was 50.5% for early RSHC and 39.0% for late RSHC. CONCLUSIONS: Mortality after RSHC is high in the current treatment era. Many patient risk factors for RSHC cannot be modified, including age, race, prior cardiac surgery, and ventricular assist device support. After RSHC, CAV is the only predictor of graft failure. Patients who have late RSHC fare worse than those who have RSHC within the first year after HT.
引用
- Kleinmahon JA, Gralla J, Kirk R, et al. Cardiac allograft vasculopathy and graft failure in pediatric heart transplant recipients after rejection with severe hemodynamic compromise. J Heart Lung Transplant. 2018. PMID: 30638837. doi:10.1016/j.healun.2018.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。